Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: Follow-up data of the MATADOR-PCI study

Luca, Leonardo De; Lenarda, Andrea Di; Rubboli, Andrea; Bolognese, Leonardo; Gonzini, Lucio; Fortuni, Federico; Navazio, Alessandro; Poletti, Fabrizio; Ledda, Antonietta; Urbinati, Stefano; Gabrielli, Domenico; Gulizia, Michele Massimo; Investigators, Matador-Pci

doi:10.1016/j.ejim.2021.03.029

Cited by 11 publications

(12 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Methodsmentioning

confidence: 99%

“…The MATADOR-PCI study [4, 5] was aimed to assess the antithrombotic management and clinical events of patients with AF admitted to Italian cardiology intensive care units (CCUs) for an ACS and undergoing PCI with stent implantation. The design and the main results of the MATADOR-PCI registry have been published previously [4, 5]. Briefly, the MATADOR-PCI was a prospective, observational, nationwide registry conducted in 76 Italian cardiology intensive care units between August 2018 and December 2019.…”

Section: Methodsmentioning

confidence: 99%

“…Briefly, the MATADOR-PCI was a prospective, observational, nationwide registry conducted in 76 Italian cardiology intensive care units between August 2018 and December 2019. All consecutive patients with AF and a confirmed diagnosis of ACS [non-ST elevation-ACS or ST-elevation myocardial infarction] undergoing PCI with at least 1 stent implantation have been included [4, 5]. A clinical follow-up at 6 months was also planned for all patients.…”

Section: Methodsmentioning

confidence: 99%

“…Patients admitted with a diagnosis of ACS at the time of enrollment but not confirmed during hospitalization, ACS treated medically, with surgical revascularization or with percutaneous coronary balloon angioplasty without stent implantation, and those not giving informed consent were excluded from the survey [4, 5].…”

Section: Methodsmentioning

confidence: 99%

“…The aim of this analysis was to analyze if the PARIS ischemic-hemorrhagic scale could be useful in patients with ACS and concomitant AF treated with coronary stenting enrolled in the prospective, observational, nationwide Management of Antithrombotic TherApy in Patients with Chronic or DevelOping AtRial Fibrillation During Hospitalization for PCI (MATADOR-PCI) registry [4, 5].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Could the PARIS Risk Scores Be Useful for the Choice of Triple versus Dual Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention?

Luca¹,

Bolognese

Rubboli

et al. 2022

Cardiology

Self Cite

View full text Add to dashboard Cite

Introduction. Current guidelines recommend dual antithrombotic therapy (DAT) for the majority of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) and suggest a short course of triple antithrombotic therapy (TAT) for those at very high thrombotic risk (TR) but low bleeding risk (BR). Methods. We analyze if the PARIS ischemic-hemorrhagic scale could be useful for the choice of antithrombotic strategy in patients with acute coronary syndromes (ACS) and AF treated with coronary stenting enrolled in the prospective, observational, nationwide MATADOR-PCI study. Results. Among the 588 patients discharged alive, a TAT was prescribed in 381 (64.8%) and DAT in 52 (8.8%) patients. According to the PARIS scoring system, 142 (24.2%) were classified as low, 244 (41.5%) as intermediate and 292 (34.3%) as high TR. In parallel, 87 (14.8%) were categorized in the low, 260 (44.2%) in the intermediate and 241 (41.0%) in the high-risk stratum for major bleedings. Crossing the various strata of the two PARIS risk scores, the largest group of patients consisted of those at high TR and BR (n=130, 22%), followed by those at intermediate risk according to both scores (n=122, 21%). At discharge, TAT was mainly used in patients at intermediate to high BR, while DAT in those at intermediate to high TR but low BR, according to the PARIS score. Conclusion. Our data suggest that some variables associated with increased TR or BR are poorly considered in the daily practice while the use of PARIS scales could help in the implementation of guidelines' recommendations.

show abstract